SOURCE: Leerink Swann & Company

September 19, 2005 12:30 ET

Leerink Swann & Company Initiates Coverage of Coley Pharmaceutical Group, Inc. (NASDAQ: COLY)

BOSTON, MA -- (MARKET WIRE) -- September 19, 2005 -- This morning, Senior Biotechnology analyst, William Tanner, Ph.D., initiated coverage of Coley Pharmaceutical Group, Inc. with an Outperform rating. He believes COLY has a compelling technology platform utilizing toll-like receptors (TLR) to activate the immune system, as validated by partnership agreements with Pfizer and Sanofi-Aventis.

About Coley Pharmaceutical Group, Inc.

Coley Pharmaceutical Group, Inc. (NASDAQ: COLY) is a biopharmaceutical company that develops TLR Therapeutics™, a new class of investigational drug candidates, which direct the human immune system to fight cancers, infectious diseases, asthma and allergy. The company has four TLR Therapeutic™ product candidates in its pipeline and is headquartered in Wellesley, Massachusetts.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2004 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp includes thousands of biomedical professionals and practicing physicians. Leerink Swann & Company is a member NASD/SIPC.

Contact Information

  • Contact:
    John I. Fitzgerald
    Leerink Swann & Company
    (617) 918-4564